Cell Therapeutics, Inc. · Seattle, WA United States (NASDAQ: CTIC)
| 501 Elliott Ave. West, Ste. 400 | Phone: 206-282-7100 |
| Seattle, WA | Fax: 206-284-6206 |
| 98119 | Toll Free: 800-215-2355 |
| United States | 
Map This Company |
Cell Therapeutics, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is developing a number of cancer-fighting compounds, including pixantrone, a treatment for non-Hodgkin's lymphoma and other tumorous cancers, and Opaxio (paclitaxel poliglumex) for non-small cell lung and ovarian cancers. The company's Systems Medicine subsidiary is working on a potential sarcoma-fighter called brostallicin. CTI no longer markets any commercial products and instead focuses on research and development projects.
Cell Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: CTIC Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 88 |
Executives
30 executives listed for Cell Therapeutics, Inc.'s Seattle, WA location.
| Chairman | Phillip Nudelman | |
|---|---|---|
| CEO and Director | James Bianco | |
| President | Craig Philips |